{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Management of Tyrosine Kinase Inhibitor Anticancer Agents with Gastric Acid Suppression Medications

Purpose of Activity

To provide information on the drug-drug interactions between gastric acid suppression agents and tyrosine kinase inhibitor anticancer treatments.

Learning Objectives/Outcomes

After completing this continuing education activity you will be able to:

  1. Summarize the indications for gastric acid suppressing (GAS) medications and the prevalence of their use among people with cancer.
  2. Analyze the implications of research findings on the effects of GAS agents on patients who also received tyrosine kinase inhibitor (TKI) anticancer treatments.
Price: $12.95

Credits:

  • ANCC 1.0 CH
  • DC - BON 1.0 CH
  • FL - BON 1.0 CH
  • GA - BON 1.0 CH

Lippincott Professional Development is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, and Georgia Board of Nursing, #50-1223.







Test Code: OT1019
Published: October 2019
Expires: 9/3/2021
Sources: Oncology Times
Passing Score: 7/10 (70%)
Authors: Lisa Lohr, PhARMD, BCOP, BCPS
Specialties: Oncology